During the past decade, Boston Baskin Cancer Group, University Tennessee Oncology/Hematology Group conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Boston Baskin Cancer Group, University Tennessee Oncology/Hematology Group" #1 sponsor was "Amgen" with 1 trials, followed by "Eli Lilly and Company" with 1 trials sponsored, "Pharmatech Oncology" with 1 trials sponsored, "Spectrum Pharmaceuticals, Inc" with 1 trials sponsored and "Theradex" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

According to Clinical.Site data, the most researched conditions in "Boston Baskin Cancer Group, University Tennessee Oncology/Hematology Group" are "Breast Cancer" (1 trials), "Leukemia" (1 trials), "Lung Cancer" (1 trials), "Lymphoma" (1 trials) and "Metastatic Cancer" (1 trials). Many other conditions were trialed in "Boston Baskin Cancer Group, University Tennessee Oncology/Hematology Group" in a lesser frequency.

Most popular intervention types in "Boston Baskin Cancer Group, University Tennessee Oncology/Hematology Group" are "Drug" (4 trials), "Biological" (2 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "BBR 3464" (1 trials), "denileukin diftitox" (1 trials), "docetaxel" (1 trials), "efaproxiral" (1 trials) and "filgrastim" (1 trials). Other intervention names were less common.

The vast majority of trials in "Boston Baskin Cancer Group, University Tennessee Oncology/Hematology Group" are 4 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Boston Baskin Cancer Group, University Tennessee Oncology/Hematology Group". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Boston Baskin Cancer Group, University Tennessee Oncology/Hematology Group, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Boston Baskin Cancer Group, University Tennessee Oncology/Hematology Group, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".